The past year has presented UnitedHealth with its most severe market challenges since the 2008 financial crisis. The healthcare behemoth, weighed down by regulatory probes, executive turnover, and withdrawn profit forecasts, is now attempting to engineer a turnaround through a sweeping independent review. As CEO Stephen Hemsley outlines specific reform measures, shareholders are left questioning whether these steps will be sufficient to bridge the deep operational and legal divides the company faces.
A Historic Year of Crisis
The stock’s performance starkly illustrates the necessity of the company’s current transparency drive. Having shed 43.15 percent of its value since the start of the year, UnitedHealth shares are on track for their worst annual performance in 17 years. This precipitous decline stems from a confluence of damaging factors:
- Regulatory Scrutiny: The U.S. Department of Justice is pursuing both criminal and civil investigations into the company’s Medicare Advantage billing practices.
- Profit Squeeze: The medical cost ratio has climbed to approximately 89 percent, significantly compressing earnings.
- Leadership Turmoil: The sudden departure of former CEO Andrew Witty in May injected further uncertainty into the situation.
Although the share price has recovered somewhat from its 52-week low of 205.45 euros, it remains nearly 48 percent below its February peak.
Operational Shortcomings Come to Light
In response to sustained criticism, UnitedHealth on December 19, 2025, released initial findings from external reviews conducted by FTI Consulting and the Analysis Group. Concurrently, the company committed to 23 action plans designed to address deficiencies in its Medicare Advantage, care management, and pharmacy services segments. According to CEO Hemsley, about 65 percent of these corrective measures are slated for implementation by year-end, with the remainder to follow by March 2026.
Should investors sell immediately? Or is it worth buying Unitedhealth?
The auditors pinpointed specific weaknesses in day-to-day operations. FTI Consulting cited excessively slow decision-making processes for prior authorizations and inconsistencies in documentation within the “HouseCalls” home-visit program. The report also urged the conglomerate to respond more swiftly and accurately to the outcomes of regulatory audits. While its OptumRx subsidiary was found to have no fundamental flaws, reviewers called for improvements in how it arbitrates payment disputes.
Bleak Earnings Forecast
These fundamental headwinds are expected to persist in upcoming financial statements. Market experts anticipate a sharp drop in profit for the 2025 fiscal year. The consensus forecast points to a decline in earnings per share (EPS) of roughly 41 percent compared to the prior year. The fourth quarter is projected to be particularly weak, with an anticipated EPS plunge of 69 percent.
The effectiveness of UnitedHealth’s pledged refocus on core operations and margin recovery will be tested on January 27, 2026. This is the date management has set to publish full-year results and provide guidance for 2026—a pivotal moment that will indicate whether a true bottom has been reached.
Ad
Unitedhealth Stock: Buy or Sell?! New Unitedhealth Analysis from December 21 delivers the answer:
The latest Unitedhealth figures speak for themselves: Urgent action needed for Unitedhealth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 21.
Unitedhealth: Buy or sell? Read more here...
